Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model

被引:131
作者
Krueckl, SL
Sikes, RA
Edlund, NM
Bell, RH
Hurtado-Coll, A
Fazli, L
Gleave, ME
Cox, ME
机构
[1] Vancouver Gen Hosp, Prostate Ctr, Dept Surg, Vancouver, BC V6H 3Z6, Canada
[2] Univ Delaware, Dept Sci Biol, Lab Canc Ontogeny & Therapeut, Newark, DE USA
[3] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA
关键词
D O I
10.1158/0008-5472.CAN-04-2446
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Apoptosis and inhibition of mitosis are primary mechanisms mediating androgen ablation therapy-induced regression of prostate cancer (PCa), However, PCa readily becomes androgen independent, leading to fatal disease. Up-regulated growth and survival signaling is implicated in development of resistance to androgen ablation therapy. We are testing the hypothesis that insulin-like growth factor (IGF) responsiveness is required for androgen-independent (AI) progression. Using the LNCaP human PCa progression model, we have determined that IGF-I-mediated protection from apoptotic stress and enhanced mitotic activity is androgen dependent in LNCaP cells but is androgen independent in lineage-derived C4-2 cells. Both cell lines exhibit androgen-responsive patterns of IGF-I receptor (IGF-IR) expression, activation, and signaling to insulin receptor substrate-2 and AKT. However, C4-2 cells express higher levels of IGF-IR mRNA and protein and exhibit enhanced IGF-I-mediated phosphorylation and downstream signaling under androgen-deprived conditions. In comparisons of naive and AI metastatic human PCa specimens, we have confirmed that IGF-IR levels are elevated in advanced disease. Together with our LNCaP/C4-2 AI progression model data, these results indicate that increased IGF-IR expression is associated with AI antiapoptotic and promitotic IGF signaling in PCa disease progression.
引用
收藏
页码:8620 / 8629
页数:10
相关论文
共 52 条
[1]   The IGF-I receptor in cancer research [J].
Baserga, R .
EXPERIMENTAL CELL RESEARCH, 1999, 253 (01) :1-6
[2]   Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics [J].
Blum, G ;
Gazit, A ;
Levitzki, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (42) :40442-40454
[3]  
Bruning JC, 1997, MOL CELL BIOL, V17, P1513
[4]   Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo [J].
Burfeind, P ;
Chernicky, CL ;
Rininsland, F ;
Ilan, J ;
Ilan, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (14) :7263-7268
[5]  
Carson JP, 1999, CANCER RES, V59, P1449
[6]  
Chan JM, 2002, J NATL CANCER I, V94, P1099
[7]   Plasma insulin-like growth factor I and prostate cancer risk: A prospective study [J].
Chan, JM ;
Stampfer, MJ ;
Giovannucci, E ;
Gann, PH ;
Ma, J ;
Wilkinson, P ;
Hennekens, CH ;
Pollak, M .
SCIENCE, 1998, 279 (5350) :563-566
[8]   INSULIN-LIKE GROWTH-FACTORS (IGFS), IGF RECEPTORS, AND IGF-BINDING PROTEINS IN PRIMARY CULTURES OF PROSTATE EPITHELIAL-CELLS [J].
COHEN, P ;
PEEHL, DM ;
LAMSON, G ;
ROSENFELD, RG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (02) :401-407
[9]  
Cox ME, 1999, CANCER RES, V59, P3821
[10]   Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice [J].
DiGiovanni, J ;
Kiguchi, K ;
Frijhoff, A ;
Wilker, E ;
Bol, DK ;
Beltrán, L ;
Moats, S ;
Ramirez, A ;
Jorcano, J ;
Conti, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3455-3460